Do analysts rate FTFT or INKT?

MiNK Therapeutics has a consensus price target of $35.00, indicating a potential upside of 209.60%. Given MiNK Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe MiNK Therapeutics is more favorable than Future FinTech Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Future FinTech Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 MiNK Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50

Does the media prefer FTFT or INKT?

In the previous week, Future FinTech Group had 8 more articles in the media than MiNK Therapeutics. MarketBeat recorded 10 mentions for Future FinTech Group and 2 mentions for MiNK Therapeutics. MiNK Therapeutics' average media sentiment score of 1.31 beat Future FinTech Group's score of 0.39 indicating that MiNK Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Future FinTech Group 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MiNK Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, INKT or NKTX?

MiNK Therapeutics is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MiNK Therapeutics N/A N/A -$12.49M -$2.84 N/A Nkarta N/A N/A -$104.08M -$1.34 N/A

Is INKT or NKTX more profitable?

MiNK Therapeutics' return on equity of 0.00% beat Nkarta's return on equity. Company Net Margins Return on Equity Return on Assets MiNK Therapeutics N/A N/A -118.57% Nkarta N/A -30.90% -24.20%

Is ALEC or INKT more profitable?

MiNK Therapeutics has a net margin of 0.00% compared to Alector's net margin of -680.83%. MiNK Therapeutics' return on equity of 0.00% beat Alector's return on equity. Company Net Margins Return on Equity Return on Assets Alector -680.83% -295.17% -40.95% MiNK Therapeutics N/A N/A -118.57%

Does the media refer more to ALEC or INKT?

In the previous week, Alector had 2 more articles in the media than MiNK Therapeutics. MarketBeat recorded 4 mentions for Alector and 2 mentions for MiNK Therapeutics. MiNK Therapeutics' average media sentiment score of 1.31 beat Alector's score of 0.11 indicating that MiNK Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alector 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MiNK Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer INKT or VYGR?

In the previous week, Voyager Therapeutics had 1 more articles in the media than MiNK Therapeutics. MarketBeat recorded 3 mentions for Voyager Therapeutics and 2 mentions for MiNK Therapeutics. MiNK Therapeutics' average media sentiment score of 1.31 beat Voyager Therapeutics' score of 0.81 indicating that MiNK Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiNK Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Voyager Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, TARA or INKT?

MiNK Therapeutics is trading at a lower price-to-earnings ratio than Protara Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Protara Therapeutics N/A N/A -$57.44M -$1.34 N/A MiNK Therapeutics N/A N/A -$12.49M -$2.84 N/A

Is TARA or INKT more profitable?

MiNK Therapeutics' return on equity of 0.00% beat Protara Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Protara Therapeutics N/A -38.70% -36.02% MiNK Therapeutics N/A N/A -118.57%

Does the media refer more to TARA or INKT?

In the previous week, Protara Therapeutics had 2 more articles in the media than MiNK Therapeutics. MarketBeat recorded 4 mentions for Protara Therapeutics and 2 mentions for MiNK Therapeutics. MiNK Therapeutics' average media sentiment score of 1.31 beat Protara Therapeutics' score of 1.23 indicating that MiNK Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protara Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MiNK Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

MiNK Therapeutics (INKT) Competitors

$11.30 +0.16 (+1.39%)

As of 02:02 PM Eastern

Compare

INKT vs. FTFT, NKTX, ALEC, VYGR, and TARA

Should you buy MiNK Therapeutics stock or one of its competitors? MarketBeat compares MiNK Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with MiNK Therapeutics include Future FinTech Group (FTFT), Nkarta (NKTX), Alector (ALEC), Voyager Therapeutics (VYGR), and Protara Therapeutics (TARA).

How does MiNK Therapeutics compare to Future FinTech Group?

Future FinTech Group (NASDAQ:FTFT) and MiNK Therapeutics (NASDAQ:INKT) are related small-cap companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and valuation.

MiNK Therapeutics has a consensus price target of $35.00, indicating a potential upside of 209.60%. Given MiNK Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe MiNK Therapeutics is more favorable than Future FinTech Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Future FinTech Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
MiNK Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

0.2% of Future FinTech Group shares are owned by institutional investors. Comparatively, 2.9% of MiNK Therapeutics shares are owned by institutional investors. 1.5% of Future FinTech Group shares are owned by insiders. Comparatively, 20.4% of MiNK Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

MiNK Therapeutics has a net margin of 0.00% compared to Future FinTech Group's net margin of -37.76%. MiNK Therapeutics' return on equity of 0.00% beat Future FinTech Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Future FinTech Group	-37.76%	-13.08%	-10.33%
MiNK Therapeutics	N/A	N/A	-118.57%

Future FinTech Group has a beta of 1.82, meaning that its stock price is 82% more volatile than the broader market. Comparatively, MiNK Therapeutics has a beta of 0.47, meaning that its stock price is 53% less volatile than the broader market.

In the previous week, Future FinTech Group had 8 more articles in the media than MiNK Therapeutics. MarketBeat recorded 10 mentions for Future FinTech Group and 2 mentions for MiNK Therapeutics. MiNK Therapeutics' average media sentiment score of 1.31 beat Future FinTech Group's score of 0.39 indicating that MiNK Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Future FinTech Group	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MiNK Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Future FinTech Group has higher revenue and earnings than MiNK Therapeutics. MiNK Therapeutics is trading at a lower price-to-earnings ratio than Future FinTech Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Future FinTech Group	$3.83M	3.16	-$4.62M	-$3.17	N/A
MiNK Therapeutics	N/A	N/A	-$12.49M	-$2.84	N/A

Summary

MiNK Therapeutics beats Future FinTech Group on 10 of the 16 factors compared between the two stocks.

How does MiNK Therapeutics compare to Nkarta?

MiNK Therapeutics (NASDAQ:INKT) and Nkarta (NASDAQ:NKTX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, media sentiment, profitability, risk and earnings.

In the previous week, MiNK Therapeutics had 1 more articles in the media than Nkarta. MarketBeat recorded 2 mentions for MiNK Therapeutics and 1 mentions for Nkarta. Nkarta's average media sentiment score of 1.87 beat MiNK Therapeutics' score of 1.31 indicating that Nkarta is being referred to more favorably in the news media.

Company	Overall Sentiment
MiNK Therapeutics	Positive
Nkarta	Very Positive

MiNK Therapeutics is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiNK Therapeutics	N/A	N/A	-$12.49M	-$2.84	N/A
Nkarta	N/A	N/A	-$104.08M	-$1.34	N/A

MiNK Therapeutics has a beta of 0.47, indicating that its stock price is 53% less volatile than the broader market. Comparatively, Nkarta has a beta of 0.9, indicating that its stock price is 10% less volatile than the broader market.

MiNK Therapeutics' return on equity of 0.00% beat Nkarta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiNK Therapeutics	N/A	N/A	-118.57%
Nkarta	N/A	-30.90%	-24.20%

MiNK Therapeutics currently has a consensus price target of $35.00, indicating a potential upside of 209.60%. Nkarta has a consensus price target of $10.75, indicating a potential upside of 294.50%. Given Nkarta's stronger consensus rating and higher possible upside, analysts plainly believe Nkarta is more favorable than MiNK Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiNK Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Nkarta	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

2.9% of MiNK Therapeutics shares are held by institutional investors. Comparatively, 80.5% of Nkarta shares are held by institutional investors. 20.4% of MiNK Therapeutics shares are held by insiders. Comparatively, 9.8% of Nkarta shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Nkarta beats MiNK Therapeutics on 9 of the 13 factors compared between the two stocks.

How does MiNK Therapeutics compare to Alector?

Alector (NASDAQ:ALEC) and MiNK Therapeutics (NASDAQ:INKT) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, media sentiment, analyst recommendations, profitability, risk, dividends and earnings.

MiNK Therapeutics has lower revenue, but higher earnings than Alector. MiNK Therapeutics is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alector	$21.05M	7.73	-$142.93M	-$1.19	N/A
MiNK Therapeutics	N/A	N/A	-$12.49M	-$2.84	N/A

MiNK Therapeutics has a net margin of 0.00% compared to Alector's net margin of -680.83%. MiNK Therapeutics' return on equity of 0.00% beat Alector's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alector	-680.83%	-295.17%	-40.95%
MiNK Therapeutics	N/A	N/A	-118.57%

Alector presently has a consensus price target of $3.63, indicating a potential upside of 147.44%. MiNK Therapeutics has a consensus price target of $35.00, indicating a potential upside of 209.60%. Given MiNK Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe MiNK Therapeutics is more favorable than Alector.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alector	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13
MiNK Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

85.8% of Alector shares are owned by institutional investors. Comparatively, 2.9% of MiNK Therapeutics shares are owned by institutional investors. 8.3% of Alector shares are owned by company insiders. Comparatively, 20.4% of MiNK Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Alector has a beta of 0.6, meaning that its stock price is 40% less volatile than the broader market. Comparatively, MiNK Therapeutics has a beta of 0.47, meaning that its stock price is 53% less volatile than the broader market.

In the previous week, Alector had 2 more articles in the media than MiNK Therapeutics. MarketBeat recorded 4 mentions for Alector and 2 mentions for MiNK Therapeutics. MiNK Therapeutics' average media sentiment score of 1.31 beat Alector's score of 0.11 indicating that MiNK Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alector	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MiNK Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Alector and MiNK Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does MiNK Therapeutics compare to Voyager Therapeutics?

MiNK Therapeutics (NASDAQ:INKT) and Voyager Therapeutics (NASDAQ:VYGR) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, earnings, dividends, risk, valuation and media sentiment.

2.9% of MiNK Therapeutics shares are owned by institutional investors. Comparatively, 48.0% of Voyager Therapeutics shares are owned by institutional investors. 20.4% of MiNK Therapeutics shares are owned by company insiders. Comparatively, 12.7% of Voyager Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

MiNK Therapeutics has higher earnings, but lower revenue than Voyager Therapeutics. MiNK Therapeutics is trading at a lower price-to-earnings ratio than Voyager Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiNK Therapeutics	N/A	N/A	-$12.49M	-$2.84	N/A
Voyager Therapeutics	$40.37M	4.87	-$119.72M	-$1.97	N/A

MiNK Therapeutics currently has a consensus target price of $35.00, suggesting a potential upside of 209.60%. Voyager Therapeutics has a consensus target price of $16.50, suggesting a potential upside of 406.91%. Given Voyager Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Voyager Therapeutics is more favorable than MiNK Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiNK Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Voyager Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

MiNK Therapeutics has a net margin of 0.00% compared to Voyager Therapeutics' net margin of -319.61%. MiNK Therapeutics' return on equity of 0.00% beat Voyager Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiNK Therapeutics	N/A	N/A	-118.57%
Voyager Therapeutics	-319.61%	-55.97%	-43.12%

MiNK Therapeutics has a beta of 0.47, meaning that its stock price is 53% less volatile than the broader market. Comparatively, Voyager Therapeutics has a beta of 1.27, meaning that its stock price is 27% more volatile than the broader market.

In the previous week, Voyager Therapeutics had 1 more articles in the media than MiNK Therapeutics. MarketBeat recorded 3 mentions for Voyager Therapeutics and 2 mentions for MiNK Therapeutics. MiNK Therapeutics' average media sentiment score of 1.31 beat Voyager Therapeutics' score of 0.81 indicating that MiNK Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiNK Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Voyager Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Voyager Therapeutics beats MiNK Therapeutics on 10 of the 15 factors compared between the two stocks.

How does MiNK Therapeutics compare to Protara Therapeutics?

Protara Therapeutics (NASDAQ:TARA) and MiNK Therapeutics (NASDAQ:INKT) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, valuation, institutional ownership, analyst recommendations and media sentiment.

MiNK Therapeutics is trading at a lower price-to-earnings ratio than Protara Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protara Therapeutics	N/A	N/A	-$57.44M	-$1.34	N/A
MiNK Therapeutics	N/A	N/A	-$12.49M	-$2.84	N/A

Protara Therapeutics currently has a consensus price target of $26.25, indicating a potential upside of 534.82%. MiNK Therapeutics has a consensus price target of $35.00, indicating a potential upside of 209.60%. Given Protara Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Protara Therapeutics is more favorable than MiNK Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protara Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
MiNK Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

MiNK Therapeutics' return on equity of 0.00% beat Protara Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protara Therapeutics	N/A	-38.70%	-36.02%
MiNK Therapeutics	N/A	N/A	-118.57%

In the previous week, Protara Therapeutics had 2 more articles in the media than MiNK Therapeutics. MarketBeat recorded 4 mentions for Protara Therapeutics and 2 mentions for MiNK Therapeutics. MiNK Therapeutics' average media sentiment score of 1.31 beat Protara Therapeutics' score of 1.23 indicating that MiNK Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protara Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MiNK Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Protara Therapeutics has a beta of 1.48, indicating that its stock price is 48% more volatile than the broader market. Comparatively, MiNK Therapeutics has a beta of 0.47, indicating that its stock price is 53% less volatile than the broader market.

38.1% of Protara Therapeutics shares are owned by institutional investors. Comparatively, 2.9% of MiNK Therapeutics shares are owned by institutional investors. 7.6% of Protara Therapeutics shares are owned by insiders. Comparatively, 20.4% of MiNK Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Protara Therapeutics beats MiNK Therapeutics on 9 of the 14 factors compared between the two stocks.

Get MiNK Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INKT vs. The Competition

Export

Metric	MiNK Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$56.30M	$3.65B	$6.75B	$12.55B
Dividend Yield	N/A	2.20%	2.68%	8.00%
P/E Ratio	-3.98	21.18	26.99	24.40
Price / Sales	N/A	312.31	585.80	117.91
Price / Cash	N/A	61.98	29.22	49.36
Price / Book	-3.73	8.59	10.86	6.35
Net Income	-$12.49M	$23.83M	$3.58B	$330.89M
7 Day Performance	6.45%	-2.91%	-1.95%	-0.87%
1 Month Performance	-5.95%	6.98%	3.47%	-0.26%
1 Year Performance	-72.16%	49.68%	26.84%	20.20%

MiNK Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INKT MiNK Therapeutics	2.8034 of 5 stars	$11.31 +1.4%	$35.00 +209.6%	-82.6%	$56.30M	N/A	N/A	30	Positive News
FTFT Future FinTech Group	0.7652 of 5 stars	$0.61 flat	N/A	-97.1%	$3.58M	$3.83M	N/A	70	Short Interest Decrease Gap Down
NKTX Nkarta	3.9647 of 5 stars	$3.22 flat	$10.75 +233.9%	+52.5%	$230.38M	N/A	N/A	140	Gap Down High Trading Volume
ALEC Alector	2.449 of 5 stars	$2.06 flat	$3.63 +76.0%	-6.2%	$228.71M	$21.05M	N/A	270
VYGR Voyager Therapeutics	3.4052 of 5 stars	$3.78 flat	$16.50 +336.5%	-7.2%	$228.39M	$40.37M	N/A	100	News Coverage Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INKT) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MiNK Therapeutics (INKT) Competitors

INKT vs. FTFT, NKTX, ALEC, VYGR, and TARA

How does MiNK Therapeutics compare to Future FinTech Group?

Summary

How does MiNK Therapeutics compare to Nkarta?

Summary

How does MiNK Therapeutics compare to Alector?

Summary

How does MiNK Therapeutics compare to Voyager Therapeutics?

Summary

How does MiNK Therapeutics compare to Protara Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INKT vs. The Competition

MiNK Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MiNK Therapeutics (INKT) Competitors

INKT vs. FTFT, NKTX, ALEC, VYGR, and TARA

How does MiNK Therapeutics compare to Future FinTech Group?

Do analysts rate FTFT or INKT?

Do insiders and institutionals believe in FTFT or INKT?

Is FTFT or INKT more profitable?

Which has more volatility and risk, FTFT or INKT?

Does the media prefer FTFT or INKT?

Which has preferable earnings & valuation, FTFT or INKT?

Summary

How does MiNK Therapeutics compare to Nkarta?

Does the media prefer INKT or NKTX?

Which has better earnings and valuation, INKT or NKTX?

Which has more volatility & risk, INKT or NKTX?

Is INKT or NKTX more profitable?

Do analysts rate INKT or NKTX?

Do insiders & institutionals hold more shares of INKT or NKTX?

Summary

How does MiNK Therapeutics compare to Alector?

Which has better earnings and valuation, ALEC or INKT?

Is ALEC or INKT more profitable?

Do analysts prefer ALEC or INKT?

Do insiders and institutionals believe in ALEC or INKT?

Which has more volatility & risk, ALEC or INKT?

Does the media refer more to ALEC or INKT?

Summary

How does MiNK Therapeutics compare to Voyager Therapeutics?

Do insiders & institutionals hold more shares of INKT or VYGR?

Which has stronger earnings & valuation, INKT or VYGR?

Do analysts recommend INKT or VYGR?

Is INKT or VYGR more profitable?

Which has more volatility & risk, INKT or VYGR?

Does the media prefer INKT or VYGR?

Summary

How does MiNK Therapeutics compare to Protara Therapeutics?

Which has preferable valuation & earnings, TARA or INKT?

Do analysts recommend TARA or INKT?

Is TARA or INKT more profitable?

Does the media refer more to TARA or INKT?

Which has more volatility and risk, TARA or INKT?

Do insiders and institutionals have more ownership in TARA or INKT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INKT vs. The Competition

MiNK Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools